Discovery of a Novel Potent and Selective HSD17B13 Inhibitor, BI-3231, a Well-Characterized Chemical Probe Available for Open Science-Reference-Cited by-同舟云学术

Discovery of a Novel Potent and Selective HSD17B13 Inhibitor, BI-3231, a Well-Characterized Chemical Probe Available for Open Science

Published:2023-02-02 Issue:4 Volume:66 Page:2832-2850
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Thamm Sven¹^ORCID,Willwacher Marina K.¹^ORCID,Aspnes Gary E.¹,Bretschneider Tom¹,Brown Nicholas F.²,Buschbom-Helmke Silke¹,Fox Thomas¹^ORCID,Gargano Emanuele M.¹,Grabowski Daniel¹,Hoenke Christoph¹,Matera Damian²,Mueck Katja¹,Peters Stefan¹,Reindl Sophia¹,Riether Doris¹^ORCID,Schmid Matthias¹,Tautermann Christofer S.¹^ORCID,Teitelbaum Aaron M.¹^ORCID,Trünkle Cornelius¹,Veser Thomas¹^ORCID,Winter Martin¹,Wortmann Lars¹^ORCID

Affiliation:

1. Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riß, Germany

2. Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, PO Box 368, Ridgefield, Connecticut 06877-0368, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c01884

Reference75 articles.

1. Beyond 2020: Modelling obesity and diabetes prevalence

2. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition